PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER

Metastatic Cancer Diagnostic and Related Therapeutics NU 2001-022 and NU 2006-026 Inventors Sui Huang* Rajesh Kamath David Spector Ann Thor Chen Wang Abstract A Northwestern researcher has identified and developed new small molecular drug candidates that target the perinucleolar compartment (PNC). The PNC has already been shown to correlate with the degree of malignancy in breast and other cancers and can be easily identified by tissue staining, ELISA and flow cytometry. The development of several antibodies that detect PNC further facilitates its identification. In addition to diagnostic capabilities, these novel compounds also show both in vitro and in vivo anti-cancer capabilities. Applications o Diagnostic: Breast Cancer o Therapeutic: Breast Cancer Advantages o Easy to detect o Existing Tools related to PNC IP Status Issued US Patent No. 7,588,904 and 8,241,862